American Association for Cancer Research: A Biologic Drug-Device Combination Immunotherapy Shows Promise for Patients With Metastatic Prostate Cancer
April 08, 2024
April 08, 2024
SAN DIEGO, California, April 8 -- The American Association for Cancer Research issued the following news release:
SYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical responses in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results reported at the American Association for Cancer Research (AACR) Annual Meeting 2024, held A . . .
SYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical responses in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results reported at the American Association for Cancer Research (AACR) Annual Meeting 2024, held A . . .